In 2012, Ciravolo and colleagues demonstrated that, in advanced breast cancer patients treated with trastuzumab, Her2+ EVs in serum behave as decoys; for this reason, the presence of these EVs could be used to predict patients’ response [152]. This evidence concerns the gene ERBB2 and breast cancer.